HUTCHMED (China) (HMDCF) Asset Writedowns and Impairment (2015)
HUTCHMED (China)'s (HMDCF) quarterly Asset Writedowns and Impairment came in at $1.3 million in Q4 2015.
Powered by 
Analysis
HUTCHMED (China) (HMDCF) Asset Writedowns and Impairment (2015) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Asset Writedowns and Impairment for 1 consecutive years, with $1.3 million the latest figure, recorded in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - |